<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03354039</url>
  </required_header>
  <id_info>
    <org_study_id>TAMDMD</org_study_id>
    <nct_id>NCT03354039</nct_id>
  </id_info>
  <brief_title>Tamoxifen in Duchenne Muscular Dystrophy</brief_title>
  <acronym>TAMDMD</acronym>
  <official_title>Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, double blind, placebo controlled, 48-week clinical trial with a core population
      (group A) of 79 ambulant 6.5 to 12 years old Duchenne's muscular dystrophy (DMD) patients
      that are under stable standard treatment of care with glucocorticoids. Furthermore, the
      investigators plan to include 16-20 non-ambulant patients who do not receive glucocorticoids
      (as parallel group B), 10 to 16 years old, to obtain efficacy and safety data in a broader
      DMD population. All patients will receive 20 mg of tamoxifen (TAM) or placebo once daily
      during 48 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 48-week multicentre, parallel, randomised, double-blind, placebo controlled phase 3
      safety and efficacy trial. There are two treatment arms: Tamoxifen (verum) and placebo
      (control), with treatment allocation of 1:1.

      The investigators plan to screen at least 79 and to enroll at least 71 ambulant DMD patients
      aged between 6.5 and 12 years (group A) and 16 - 20 non-ambulant DMD patients aged between 10
      and 16 years (group B). In order to reach statistical power, 60 ambulant patients (group A)
      need to complete the trial. Treatment with 20 mg Tamoxifen once daily will be given for the
      total trial duration of 48 weeks.

      Only patients with glucocorticoids (standard treatment of care) will be included in group A
      (ambulant patients) and only non-glucocorticoid users in group B. At baseline as well as at
      the end of the study clinical, laboratory, and MRI measurements will be performed. These
      include the Motor Function Measure (MFM) scale, timed function tests, the 6 minute walking
      distance, quantitative muscle testing (QMT) and quantitative thigh muscle MRI,
      questionnaires. A physical examination, an ECG, vital signs as well as safety laboratory
      blood analyses will be performed at every visit. Furthermore, an x-ray of the hand and a dual
      energy x-ray absorptiometry (DEXA)-scan will be performed at baseline and at the end of the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of disease progression</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>To test if tamoxifen treatment, compared to placebo, reduces the progression of the disease in 6.5-12 years old ambulant DMD patients (Group A) by at least 50% (using the MFM D1 subscore as primary clinical endpoint).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle function measured by D2 MFM subscore</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>D2 MFM subscore from baseline to week 48 under TAM treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function measured by D3 MFM subscore</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>D3 MFM subscore from baseline to week 48 under TAM treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function measured by North Star Ambulatory Assessment</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>North Star Ambulatory Assessment from baseline to week 48 under TAM treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function measured by proximal upper limb function</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>Proximal upper limb function from baseline to week 48 under TAM treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function measured by 6 minute walking distance in meter</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>6 minute walking distance in meter from baseline to week 48 under TAM treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function measured by 10 meter walking time in seconds</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>10 meter walking time in seconds from baseline to week 48 under TAM treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function measured by time to rise from lying on the floor / supine up in seconds</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>time to rise from lying on the floor / supine up in seconds from baseline to week 48 under TAM treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle force measured by quantitative muscle testing (using Myogrip)</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>Quantitative muscle testing (using Myogrip) from baseline to week 48 under TAM treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Degeneration measured by MRI</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>Quantitative muscle MRI including muscle fat fraction (MFF) and T2 times of thigh muscles visualised by MRI from baseline to week 48 under TAM treatment compared to placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient reported outcome measured by PARS III questionnaire</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>Personal Adjustment and Role Skills Scale (PARS-III) from baseline to week 48 under TAM treatment under TAM treatment compared to placebo.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Tamoxifen 20 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of TAM daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomised to placebo will be administered matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.</description>
    <arm_group_label>Tamoxifen 20 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.</description>
    <arm_group_label>Matching placebo once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group A (ambulant patients)

          -  Documented diagnosis of DMD by mutation analysis in the dystrophin gene or by
             substantially reduced levels of dystrophin protein (i.e. absent or &lt;5% of normal) on
             Western blot or immunostaining

          -  Stable treatment with glucocorticoids &gt;6 months (no significant change in dosage
             (&gt;0.2mg/kg)) at screening; dosing adaptations according to weight change are allowed

          -  Male gender

          -  6.5 to 12 years of age at time of screening

          -  weight &gt;15kg

          -  ambulant patients

          -  able to walk at least 350 meters in 6 minute walking distance test without assistance

          -  MFM D1 subdomain of the MFM scale &gt;40% at screening

          -  Ability to provide informed consent and to comply with study requirements

        Group B (non-ambulant patients)

          -  Documented diagnosis of DMD by mutation analysis in the dystrophin gene or by
             substantially reduced levels of dystrophin protein (i.e. absent or &lt;5% of normal) on
             Western blot or immunostaining

          -  Not using glucocorticoids for &gt;6 months

          -  Male gender

          -  Non-ambulant patients (walking distance less than 10 meters)

          -  10 to 16 years of age at time of screening

          -  Ability to provide informed consent and to comply with study requirements

        Exclusion Criteria:

          -  Known individual hypersensitivity or allergy to tamoxifen

          -  Female gender

          -  Use of tamoxifen or testosterone within the last 3 months

          -  Known or suspected malignancy

          -  Other chronic disease or clinically relevant limitation of renal, liver or heart
             function

          -  Known or suspected non-compliance

          -  Any injury which may impact functional testing, e.g. upper or lower limb fracture

          -  Planned or expected spinal fusion surgery during the study period (as judged by the
             Investigator; i.e. due to rapid progressing scoliosis), previous spinal fusion surgery
             is allowed if it took place more than 6 months prior to screening.

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders of the participant/parents (as judged by the investigator)

          -  Concomitant participation in any other interventional trial (and up to 3 months prior
             to screening)

        Group A:

          -  Glucocorticoid na√Øve patients

          -  Start of glucocorticoid treatment or change in dosage &lt;6 month prior to screening
             (dosing adaptations according to weight change are allowed)

        Group B:

          -  Glucocorticoid treated patients or patients that stopped glucocorticoid treatment &lt;6
             month prior to screening

          -  Assisted ventilation of any kind necessary
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>78 Months</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Fischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk Fischer, MD</last_name>
    <phone>+41 61 704 12 12</phone>
    <email>admin-tamdmd@ukbb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Schmidt, MD</last_name>
    <phone>+41 61 704 12 12</phone>
    <email>admin-tamdmd@ukbb.ch</email>
  </overall_contact_backup>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

